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Abstract—Antimicrobial peptides (AMPs) which predominantly act via membrane active mechanisms have 
emerged as an exciting class of antimicrobial agents with tremendous potential to overcome the global 
epidemic of antibiotics-resistant infections. The first generation of AMPs derived from natural sources as 
diverse as plants, insects and humans has provided a wealth of compositional and structural information to 
design novel synthetic AMPs with enhanced antimicrobial potencies and selectivities, reduced cost of 
production due to shorter sequences and improved stabilities under physiological conditions. As a rational 
result we discovered for the first time the GENEA-Antimamphiler-109 utilizing threading/structure-based 
BIOGENETOLIGANDOROLTM Rational Strategies employed for the in silico design and optimization of 
synthetic antimicrobial peptide mimic amphiphile-based pharmacophoric agents with promising enhanced 
therapeutic potentials introducing the iview: an interactive WebGL visualizer for protein-ligand complex 
through a subpocket analysis method for fragment-based drug discovery through a KNIME-Shared 
BiogenetoligandorolTM binding site amino acid predicted similarity subpockets.  
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INTRODUCTION 
The PB model is one of the mesoscopic theories that 
describes the electrostatic potential and equilibrium 
distribution of mobile ions around molecules in 
solution. It serves as a tool to characterize 
electrostatic properties of molecules, counterion 
association, electrostatic contributions to solvation, 
and molecular binding free energies. In previous 
studies they were focused on general formulations 
which can be applied to large molecules of arbitrary 
shape in all-atomic representation, including highly 
charged biomolecules such as nucleic acids. These 
molecules present a challenge for theoretical 
description, because the conventional PB model 
may become insufficient in those cases [1]. By 
collecting as many descriptors/parameters as 
possible within a single database, it has also be  
achieved a better use of the available data and 
information showing furthermore that data grouping 
allows us to generate different parameters with the 
potential to provide new insights into the sequence–
structure–function relationship. Residue selection 
can be performed according to multiple criteria and 
can simultaneously display and analyze all the 
physicochemical parameters of any pair of 
structures, using precalculated structural alignments, 
allowing direct parameter comparison at 
corresponding amino acid positions among 
homologous structures [3]. Common strategies 
were also employed in the design and 
optimization of synthetic AMPs, followed by 
highlighting the various approaches utilized to 
enhance the therapeutic potentials of designed 
AMPs under physiological conditions taken 
advantage into the tastly, future perspectives 
on the development of improved AMPs for 
therapeutic applications as they have been 
presented. Visualization of protein-ligand 
complex plays an important role in elaborating 
protein-ligand interactions and aiding novel 
drug design where most existing web 
visualizers either rely on slow software 
rendering, or lack virtual reality support. While 
the bioavailability of AMPs is often reduced 
due to protease activity, the non-natural 
structure of AMP mimetics renders them 
robust to proteolytic degradation, thus offering 
a distinct advantage for their clinical 
application exploring the therapeutic potential 
of N-substituted glycines, or peptoids as AMP 
mimics using a multi-faceted approach that 
includes in silico, in vitro, and in vivo 
techniques reporting a new QSAR model that 
we developed based on 27 diverse peptoid 
sequences, which accurately correlates 
antimicrobial peptoid structure with 
antimicrobial activity [36]. A number of 
peptoids have also been identified that have 
potent, broad-spectrum in vitro activity against 
multi-drug resistant bacterial strains using a 
murine model of invasive S. aureus infection 
demonstrating that one of the best candidate 
peptoids at 4 mg/kg significantly reduces with 
a two-log order the bacterial counts compared 
with saline-treated controls. Although two 
binding amphiphile sites might be dissimilar 
overall, they might still bind the same 
fragments if they share suitable subpockets. 
Information about shared subpockets can be 
therefore used in fragment-based drug design 
to suggest new fragments or to replace existing 
fragments within an already known compound 
on computational methods which allows the 
similarity searching and alignment of 
subpockets from a PDB-wide database against 
a user-defined query as a innovative method 
which is based on pharmacophoric fingerprints 
combined with a subpocket alignment 
algorithm. Other bioinformatics tools was 
shown to be effective producing reasonable 
alignments for subpockets with low sequence 
similarity and be able to retrieve relevant 
subpockets from a large database of structures 
including those with different folds. It can also 
be used to analyze subpockets inside a protein 
family to facilitate drug design and to 
rationalize compound selectivity utilising 
virtual ligand screening as an integral part of 
the modern drug discovery process. Taken 
together, our results we demonstrated a 
promising in silico drug discovery 
methodology for the generation of peptoid-
mimicking multi-targeted compounds  as novel 
antimicrobial agents supporting four surface 
representations including Van der Waals 
surface, solvent excluded surface, solvent 
accessible surface and molecular surface based 
on the feature-rich version of our simulation 
meta-node sequential solution analysis of the 
Poisson-Boltzmann Equation on synthetically 
(AMPs) peptidomimetics for protein-ligand 
docking purpose.  
METHODS AND MATERIALS 
Initial virtual screening Docking results 
analysis and a Simulation meta-node 
sequential solution analysis of the Poisson-
Boltzmann Equation on synthetically 
(AMPs) peptidomimetics.   
In this article, a novel simulation meta-node 
sequential solution of the Poisson-Boltzmann 
Equation was applied on a drug discovery 
combination index dynamic unified theorem 
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for Multiple Entities for finding of maximal 
bioactivity accesible synthetically (AMPs) 
peptidomimetic-similar to an amphiphile-based 
pharmacophoric agent as a promising 
enhanced therapeutic innovative designed 
antimicrobial agent. B-lactams (cefotaxime, 
ceftazidime, cefepime, cefuroxime, faropenem, 
imipenem, meropenem, penicillin G, 
piperacillin) and hydrolyzed ampicillin, L-
captopri, ampicillin and other molecular 
structures downloaded from ZINC database, 
fragmented and then were multi-docked into 
the (AMPs) short linear motif binding peptide 
active site using parallel and re-docking 
simulations in according to the following 
computer-aasisted virtual screening procedures 
where by predicting the protein=peptide 
combile binding targets of a compound ‘rule of 
0.5’ for the metabolite-duggable-likeness of 
approved pharmaceutical drugs revealing a 
fixed target y, a prediction function hy(x) in 
the docking grid box which was generated 
around the data set of short linear repeated 
active sites using the site finder in the 
dimensions of the cross-docked parallel ligand 
docking box which were recored and cross 
docked manipulated to accommodate all the 
conserved amino acid residues present in the 
binding active pharmacophoric site.  
Figure 1. Default docking parameters were used for 
all virtual screening computational drug discovery 
procedures unless otherwise stated. A virtual 
collection of query referenced drugbank database 
derived drug-like compounds bioactive subset taken 
from ZINC database the first filters containing 
2,800,000 polynomial compounds was maximal 
served as the comprehensive screening library [39]. 
The hits with firm binding conformations were 
lacking collected and redocked fingerprinted into 
the configuration active site using the igmemdock 
protocol in settings the ADS nodes. Those similar 
pharmacophoric compounds with high free energy 
igemdock fitness scoring were selected as a 
threshold focused library used for the further 
analysis. Total binding Energy retained calculations 
and a construction metanode analysis of docking 
conformational poses were performed in resulting 
protein-inhibitor on protein- synthetically (AMPs) 
peptidomimetic complexes which were analyzed 
using the protein-peptide–short linear motif like 
ligand interaction fingerprint implemented in the 





In this scientific article we computer  designed 
a more accessible synthetically (AMPs) 
peptidomimetic-similar to an amphiphile-based 
pharmacophoric agent to be used most 
effectively indicating that ligand-based 
methods require enough known small ligands 
for targeting peptide-protein complexes of 
interest, which may be hardly accessible in 
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practice where nA is the number of conserved 
conformated patches in the peptide binding 
protein pocket A. N is the number of metrging 
and matching patch pair pharmacophores 
between binding pocket A  and recored merged 
ligand B. pdist is the distance fitness in parallel 
docking score of two merged pharmacophoric 
patches as defined in Equation 
(5). mA,B contains the high free energy list of 
matched and merged pharmacophoric patch 
pairs from binding pockets A and the generates 
hyperligand ligand B. The second term is the 
geodesic low mass stochastic predictive 
relative position difference averaged over all 
the merging and linked pharmacophoric 
matching ligand data set patches: 
BindingDB tables, structural superposition 
and a optimization comparative analysis of 
the 21 peptidomimetic crystal structures to 
motif accesible synthetically (AMPs).  
Building the BindingDB tables for the 
therapeutic antimicrobial agent we generated a 
more efficient structural superposition and a 
optimization comparative analysis which was 
based on simulated prediction models of 
mutational aligned motifs in the protein 
promoter from K-longest paths to motif 
accesible synthetically (AMPs) 
peptidomimetic-similar resulting in a merged 
amphiphile-based pharmacophoric cluster of 
agents as a structural superposition data set of 
the 22 reported (AMPs) targeted structures 
using force field pertubatuion realignment and 
refined with gaussian distance ligand to small 
compound weights showing that the most of 
the independently solved moleculars multi-
targeted structures shared a high degree of 
structural pharmacophoric motif element 
similarity with each other. It is easy to use the 
K-longest paths algorithm to predict a motif by
simply loading the K peptides to an existing
motif tool.
Figure 2: Generic String kernel Molecular-and 
Brownian dynamics superbug strains on 
predicted Tanimoto distances to virtual peptide 
short linear  motif screened of the merged 
synthetically (AMPs) peptidomimetic-similar. 
Structure-based screening and a motif analysis 
analysis on a polytriangle matcher pharmacophoric 
merger placement in silkico method, followed by 
quantum mechanic molecular modeling  mechanics 
refinement and scoring, was used for the first round 
in parallele ligand fragment based docking based 
screening dynamic process. The encoding placement 
stages were simulated and scored by E_place. 
Binding total free energy values were timescaled 
quantified using London dG [52] and Affinity dG 
[53]. After 1000 binding suited motif peptide like 
orientations for each merged compound were in 
package DUD refined where 30 conformations with 
lowest fingerprinting based calculated binding free 
energy with a consensus lowest predicting affinity 
dG and London dG fitness reader node values were 
produced.A Phenotype-based simulated method was 
generated here for protein target predictions on 
rational elaborated common strategies within 
combinatorial search problems employed for the 
efficient in silico optimization of an accesible 
synthetically (AMPs) peptidomimetic-similar to an 
amphiphile-based pharmacophoric agent on QSAR 
mimic modeling to NeoLigand34845B displacement 
assay. In silico (AMPs)  ensembles on phenotype 
protein-protein docking-based methods for Protein 
Target Prediction on QSAR mimic pharmacophore 
modeling. Phenotype-based methods is a prominent 
part of the drug development process used for 
identifying drug candidate compounds with a 
desired phenotype QSAR where descriptors were 
calculated using Molecular Operating Environment 
where a total of 3233 descriptors were initially 
calculated based on a three-dimensional structure 
estimated from energy minimization using the 
generalized Born solvation model 
In this case, the motif is a property of the 
learned model hy(x) as opposed to a consensus 
among known binding sequences where 
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workflows included do not use web-services, 
but instead use a KNIME Table Reader node to 
load a local data table of BindingDB data 
predicting. 
Molecular dynamics simulations of (AMPs) 
on Dynamic Network Binding  
PSXXNWMN and CAXXMP bioactivity 
motifs. 
In this section dynamic drug discovery 
quantum networks were generated whose 
molecular structure may change and formulate 
metanode clusters in terms of time-grid box 
similarity series depending on various protein 
proximity interaction factors to demonstrate 
the bioactive binding ability of the proposed 
approach to predict molecular dynamic 
potential simulations on functional short linear 
motifs compare to ligand and fragment 
position-specific weight matrix in 
(PSXXNWMN and CAXXMP) conserved 
sites as they can be illustrated as a 
pharmacophoric motif simulations for both 
(AMPs) which were performed using 
GROMACS 4.5.5[53]with AMBER-03 force 
field[54] running on a Linux cluster (64 bit 
processor). The dynamic metanode 
pharmacophore merging computer networks 
generated in this work are more challenging 
compared to the static network, since dynamic 
multi-targeted network simulations may 
generate of more high resolution data hidden 
model for all peptides-ligand hybrid 
chemogenomic complexes such as our 
accesible synthetically (AMPs) 
peptidomimetic-similars to an amphiphile-
based pharmacophoric agent in detailed refined 
this dataset from the rest of the discussed 
procedure.  
 
Figure 3: Using only the data subsettings predictor 
hrandom-knime-igemdock,redoking trained on R = 
2,000 randomly generated short linear mtif peptides, 
we generated the binding interactions to a motif 
representing flexible pathway network where the K 
= 3,000 best inhibitor predicted ligand-peptides 
(according to hrandom) simulation parameters 
including solvation energy prediction using cubic 
pathway boxes filled with SPC218376 water 
molecules. RMSD periodic initial calculations on 
predicted boundary central criterion conditions, 
where the merged hyperligand was complemented 
added with feTIP3P water and modulated in 
removing charge-neutralizing Na+ and Cl− ions, 
with different heavy atoms for the PME 
electrostatic interaction. Van der Waals non-bonded 
QSAR modeling interaction were better than 
traditional single conformer based on the cutoff of 
9Å with a 3fs time step binding interactions which 
was proven that the hyper merged generated 
hyperligand interact with the residues used 
ARG2276 and ASP923 more than 2000kcal/Mol/A 
during virtual docking simulations. Within the 
shallow pocket of the designed hyperligand we were 
able to recover all the small molecule and then 
linking the fragment binding pharmacophoric 
domains to improve the computational predictions 
utilizing more complex free energy based funtions 
such as QM/MM, MM/PBSA, and MM/GBSA to 
lead to optimized reference short linear motif 
pharmacophoric signals using only weakly active 
conserved redocked peptides to push the virtual 
screening analysis of the large librtaries even 
further.  
RESULTS AND DISCUSSIONS 
In this scientific article novel computer-aided 
Drug discovery motif based path network 
methodologies were incorporated for the in 
siico generated of complex  peptidomimetic 
crystal structures binding to the motif accesible 
synthetically (AMPs) focuses more on 
recognition of the optimal drug targets that can 
be utilized to produce a strengthen docking 
effect utilizing molecular dynamics 
simulations of (AMPs) on Dynamic Network 
Binding  PSXXNWMN and CAXXMP 
bioactivity motifs. Our in silico procedure is 
highly free energy efficient compared to other 
fragment ligand based approaches, where all 
ranking top hit interactome peptide-protein 
complex combinations of the hyper ligand 
generated conformers indicating that building 
QSAR models and stochastic optimization 
processes offers the optimal conditions to 
select the best performing merged 
pharmacophoric models. BindingDB tables, 
structural superposition and a optimization 
comparative analysis of the 21 peptidomimetic 
crystal structures to motif accesible 
synthetically (AMPs) were also applied in this 
scientific work revealing a novel  major 
property required for the generation of an ideal 
recored drug target  as  biological rationale to 
represent an multi-targetd consensus inhibitor 
molecule, with improved conformational 
flexibility which is taken into account in our 
across network energy functions in selected 
QSAR models as better than traditional single 
multiple conformer based on identified 3D 
QSAR reductionism drug discovery 
techniques.  Predicted boundary central 
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criterion virtual interactions of the  peptide-
protein redocking complexes with the 
generated merged Neo-ligand as can be seen 
from (Fig. 2) showing the result obtained from 
the docking parallel cubic pathway simulation 
which  has proved that the generated cross 
hyperligand compound binding interactions 
with residues ARG2276 and ASP932 were 
fully centralized consistent with the previous 
report [7] providing an efficient ideal drug 
modulated peptide protein target modulated by 
a stabile small  hypermolecule comprising 
multiple pharmacophoric domains which could 
be defined as a mimic peptide macromolecule 
(most often a protein) whose molecular 
mechanics trajectory manipulation analysis 
could result in an initial virtual screening 
Docking results analysis and a Simulation 
meta-node sequential solution analysis of the 
Poisson-Boltzmann Equation on synthetically 
(AMPs) peptidomimetics.  
CONCLUSIONS 
Validation and parallel docking simulation 
combinatorial drug discovery chemical 
genomic protocol were incorporated for the 
prediction of  the binding activity of the split 
and pool peptoid short linear motif protein-
hyper ligand- peptide complexes based on free 
energy mimicking packages which were 
synthesed on accesible synthetically (AMPs) 
peptidomimetic-similar to an amphiphile-based 
pharmacophoric agent as shown to the 
(Figure1). Rational Elaborated common ligand 
based drug discovery strategies were also 
invented within combinatorial chemical 
bioinformatics search problem employed for 
the improvement o an efficient in silico 
generation of an accesible synthetically unified 
(AMPs) peptidomimetic-similar to an 
amphiphile hyper mimicking pharmacophoric 
agent targeting on QSAR mimic modulator 
modeling to our NeoLigand34845B as 
revealed to the (Figure3). A combinatorial 
search problem was also solved where these 
merged pharmacophore fingerprinted 
signatures led to the generation of a predictive 
pharmacophore models that predict a 
druggable environment network where 
metanodes combinations were utilized as a and 
neighborhoods Sequential Solution of the 
Poisson-Boltzmann Equation on a 
Combination Index Dynamic Unified Theorem 
for Multiple Entities for finding of maximal 
bioactivity with an average accuracy of 83% as 
presented in the Figure 2. As well as 
identifying multiple targets of approved drugs, 
our machine learning artificial network based 
prediction druggable models described here 
identified active snall ligand like fragments on 
both potentially druggable targets providing a 
Fragment-based approaches and MD-based 
virtual screening method independent and 
complementary for assessing the suitability of 
a target for therapeutic future modulation. A 
Generic String kernel Molecular- and 
Brownian dynamics approaches were also 
applied as  possible drug discovery 
applications at different quantum levels of a 
novel hyper agonistic virtual chemical 
structure for the modeling of the cross docking 
reactions simulated by antimicrobial testings 
against superbug strain models. This 
incorporated unified  hollistic reaction kinetics 
approaches indicated that more scientific work 
has to be delivered on the optimization of the 
Atom Particle Diffusion pharmacophore 
structure predictions simulated relative 
Particle-Based Reaction-Diffusion Dynamics 
in virtual screend Crowded hyper ligand 
Cellular ineraction Environments. The 
computer aided assited methods presented in 
this study use only docking hyper ligand 
network parameters and the data default 
training setting include multiple conserved 
targets of all approved drug therapeutics and 
not just small ligand like molecule referenced 
drugs. Despite this, the consensus output of our 
virtual docking and virtual fragment based 
ligand shortest path connected network models 
showed strong similarity with the equal output 
from other polyorthogonal in silico methods 
that use 3D structural crystallography 
information or ligand peptide-protein binding 
data to predict the free energy and total fitness 
scorring druggability. To enable the research 
drug discovery community to use our 
clustering methodologies for objective and 
independent peptide ligand drug discovery 
methodologies based on merged hyper ligand 
generated target prioritizations, we have 
provided the results of our path associated 
common motif peptide associated network-
based predictions alongside fragment structure-
based and ligand-predictive based  results 
within this scientific work as a promising 
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example for the enhanced in silico production 
of an novel annotated antimicrobial agent. 
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